United Arab Emirates (UAE) Vaccines Market Overview, 2028

United Arab Emirates (UAE) Vaccines Market Overview, 2028

Vaccines are one of the most cost-effective and efficient public health interventions of all time, saving millions of lives each year. Vaccination is considered a crucial strategy in mitigating spread, from infection which is devastating impacts on humankind with high death tolls and significant disruptions to economies and everyday life. According to the World Health Organization (WHO), vaccination is a simple, safe, and effective way of protecting people against harmful diseases before coming into contact with them. It uses body's natural defenses to build resistance to specific infections and make immune system stronger. The United Arab Emirates (UAE) has been proactive in its response to the pandemic and has established several vaccine associations and initiatives to ensure the widespread distribution of vaccines. One of the key organizations in this regard is the Ministry of Health and Prevention (MOHAP), which has been responsible for overseeing the procurement and distribution of vaccines across the UAE. The UAE has also partnered with several pharmaceutical companies and organizations, such as Sinopharm, Pfizer-BioNTech, and AstraZeneca, to procure a variety of vaccines to cater to its population's needs. Additionally, the UAE has actively engaged in vaccine diplomacy by donating and supplying vaccines to other countries in need, particularly to those in the Middle East and North Africa region. The UAE introduced a digital health passport system that allowed vaccinated individuals to demonstrate their vaccination status when entering public places, traveling, or participating in various activities. This helped in reopening the economy and returning to a sense of normalcy. The UAE's updated AlHosn app includes vaccine records for children up to the age of 18. Doctors in the country say the government's recent move to integrate vaccine records will significantly contribute to attaining a greater nationwide child immunization rate.

According to the research report, “United Arab Emirates Vaccine Market Overview, 2028” published by Bonafide Research, the market was valued at more than USD 190 Million in 2022. The United Arab Emirates (UAE) has witnessed a significant increase in the intake of vaccines, contributing to the overall growth of the vaccine market in the country. The UAE government has demonstrated a strong commitment to public health by actively promoting and facilitating vaccine distribution. Their efficient and organized vaccination campaigns have instilled confidence in the population. The UAE's approach of importing and offering a diverse range of vaccines has attracted a broad spectrum of individuals. This diversity allows people to choose vaccines that align with their preferences and medical conditions, thereby increasing overall vaccine acceptance. The widespread availability of vaccination centers and mobile units across all Emirates has ensured that vaccines are easily accessible to residents, including those in remote or underserved areas. The UAE's vaccination process is known for its efficiency, short waiting times, and seamless booking systems. These factors have encouraged more people to get vaccinated as the process is both quick and convenient. One of the essential factors for the success of the vaccination program in the UAE is the efficient Supply Chain and Logistics systems. The UAE ranks fifth globally when it comes to vaccines availability, after the US, China, UK, and Israel, thus contributing to the overall growth of the vaccine market.

Different vaccine technologies are employed depending on the pathogen (bacteria or virus) that is being targeted. Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, and Toxoid vaccinations are all included in this technology. In the United Arab Emirates (UAE), the vaccine market in 2022 was characterized by the dominance of conjugated vaccines, with recombinant vaccines closely following suit. Conjugated vaccines, which combine a bacterial or viral component with a carrier protein, have gained prominence for their effectiveness in preventing various infectious diseases. They have been instrumental in the UAE's efforts to control and eradicate diseases like Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, particularly among children. Following closely behind, recombinant vaccines have also made significant strides in the UAE's vaccine market. These vaccines are developed using genetic engineering techniques and have proven to be highly effective against diseases such as hepatitis B and human papillomavirus (HPV). The UAE's healthcare system has recognized the importance of recombinant vaccines in preventing these infections and has integrated them into their immunization programs.

The market is divided into intramuscular and subcutaneous administration, oral administrations, and others (intranasal droplets, transdermal patches, oral-mucosal vaccines, microneedle patches, jet injectors, intraperitoneal administration, etc.) based on the route of administration. There is a suggested administration site and method for each vaccine. Each vaccine's package insert from the manufacturer contains this information. It is achievable to administer vaccines orally, usually in the form of a liquid, pill, or sugar cube. This method of vaccination has a number of benefits and has proven notably helpful in the worldwide campaign to immunize huge populations, especially in poor nations. The simplicity of administration of oral vaccinations is a major benefit. They do not require needles or syringes, which can reduce the fear and discomfort associated with vaccination. This makes oral vaccines particularly well-suited for vaccinating children, who may be more receptive to a less invasive method. Additionally, the absence of needles reduces the risk of needle injuries, making the vaccination process safer for healthcare workers. Oral vaccines are often used for diseases that primarily infect the gastrointestinal tract, such as polio and cholera

Considered in this report:
• Geography: United Arab Emirates (UAE)
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• United Arab Emirates (UAE) Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.